Brain imaging identifies biomarkers of mental illness

Research and treatment of psychiatric disorders are stymied by a lack of biomarkers – objective biological or physiological markers that can help diagnose, track, predict, and treat diseases. In a new study 新しいタブ／ウィンドウで開く, researchers use a very large dataset to identify predictive brain imaging-based biomarkers of mental illness in adolescents. The work appears in Biological Psychiatry 新しいタブ／ウィンドウで開く, published by Elsevier.

Traditionally, psychiatric disorders such as depression have been diagnosed based on symptoms according to subjective assessments. The identification of biomarkers to aid in diagnosis and treatment selection would greatly advance treatments.

In the current study, the investigators used brain imaging data from the Adolescent Brain Cognitive Development (ABCD) Study of nearly 12,000 children aged 9 to 10 at the beginning of the study. Modern neuroimaging techniques, including resting-state functional connectivity (rsFC) analysis, allow researchers to investigate the organization of brain circuits through their interaction with one another over time.

Yihong Yang, PhD, senior author of the study, at the Neuroimaging Research Branch, National Institute on Drug Abuse, said, “Using a functional MRI dataset, we identified a brain connectivity variate that is positively correlated with cognitive functions and negatively correlated with psychopathological measures.”

Cognition has long been studied in the context of mental disorders, and recent research has pointed to shared neurobiology between the two, as supported in this new study.

This brain-based variate predicted how many psychiatric disorders were identified in participants at the time of the scan and over the following two years. It also predicted the transition of diagnosis across disorders over the two-year follow-up period.”

Dr. Yang added, “These findings provide evidence for a transdiagnostic brain-based measure that underlies individual differences in developing psychiatric disorders in early adolescence.”

John Krystal, MD, Editor of Biological Psychiatry, said of the work, "Mental illness in adolescence has emerged as a cardinal public health challenge in the post-COVID era. More than ever before, we would benefit from better ways to identify adolescents at risk. This study uses data from the landmark ABCD Study to illustrate how neuroimaging data could illuminate risk for mental illness across the spectrum of diagnoses.”

Dr. Yang added, “Finding biomarkers of mental illnesses, rather than relying on symptoms, may provide a more precise means of diagnosis, and thereby aligning psychiatric diagnosis with other medical diagnoses.”

---

Notes for editors

The article is "Brain Functional Connectome Defines a Transdiagnostic Dimension Shared by Cognitive Function and Psychopathology in Preadolescents," by Xiang Xiao, Christopher Hammond, Betty Jo Salmeron, Danni Wang, Hong Gu, Tianye Zhai, Hieu Nguyen, Hanbing Lu, Thomas J. Ross, and Yihong Yang (https://doi.org/10.1016/j.biopsych.2023.08.028 新しいタブ／ウィンドウで開く). It appears online as an Article in Press in Biological Psychiatry, published by Elsevier.

Copies of this paper are available to credentialed journalists upon request; please contact Rhiannon Bugno at [email protected] 新しいタブ／ウィンドウで開く. Journalists wishing to interview the authors may contact Yihong Yang, PhD, at [email protected] 新しいタブ／ウィンドウで開く.

The authors’ affiliations and disclosures of financial and conflicts of interests are available in the article.

John H. Krystal, MD, is Chairman of the Department of Psychiatry at the Yale University School of Medicine, Chief of Psychiatry at Yale-New Haven Hospital, and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available here 新しいタブ／ウィンドウで開く.

About Biological Psychiatry

Biological Psychiatry 新しいタブ／ウィンドウで開く is the official journal of the Society of Biological Psychiatry 新しいタブ／ウィンドウで開く, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms, and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal publishes both basic and clinical contributions from all disciplines and research areas relevant to the pathophysiology and treatment of major psychiatric disorders.

The journal publishes novel results of original research which represent an important new lead or significant impact on the field, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Reviews and commentaries that focus on topics of current research and interest are also encouraged.

Biological Psychiatry is one of the most selective and highly cited journals in the field of psychiatric neuroscience. It is ranked 12^th out of 155 Psychiatry titles and 17^th out of 272 Neurosciences titles in Journal Citation Reports^TM published by Clarivate Analytics. The 2022 Impact Factor for Biological Psychiatry is 10.6. www.biologicalpsychiatryjournal.com 新しいタブ／ウィンドウで開く

エルゼビアについて

エルゼビアは情報分析を専門としたグローバル企業として、研究者や医療専門家の方々を支援し、社会にとっての利益最大化に向けて、科学や医療の進展を支えています。これは、信頼できるエビデンスによるコンテンツと高度なAI対応によるデジタル技術に基づく革新的なソリューションにより、知見の集積や重要な意思決定を支援することで実現されています。

エルゼビアは、全世界で9,700人の従業員（うち技術者2,300人以上）を抱え、140年以上にわたって、研究者、図書館員、アカデミックリーダー、資金提供者、政府、研究開発集約型企業、医師、看護師、将来の医療専門家、教育者など研究・医療分野におけるパートナーの重要な活動を支援してきました。エルゼビアが刊行する3,000誌以上の科学ジャーナルと代表的な参考書には、The Lancet 新しいタブ／ウィンドウで開く、Cell Press 新しいタブ／ウィンドウで開くおよびGray’s Anatomyなどをはじめとする、各分野を代表する主要なタイトルが含まれています。 エルゼビア・ファンデーション 新しいタブ／ウィンドウで開くとの活動を通し、私たちがサービスを提供する地域社会と連携して、開発途上国を含む世界中の医学、研究、医療分野における、インクルージョン＆ダイバーシティ（I&D）の改善に努めています。

エルゼビアは、専門家および企業向けの情報分析および意思決定ツールのグローバルプロバイダーであるRELX Group 新しいタブ／ウィンドウで開くの一事業を担っています。エルゼビアの事業内容、デジタルソリューション、コンテンツなどの詳細については、www.elsevier.comをご覧ください。